CAS 127-07-1 Hydroxyurea

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Model NO.: TY-02AL
• CAS No.: 127-07-1
• Appearance: White Powder
• Einecs: 616-396-9
• Assay: 99%
• Shelf: 2 Years
• Transport Package: 25kg/Drum1g, 50g, 500g, 1kg, 10kg, 100kg, 200kg
• Specification: 25kg/drum
• Trademark: tongyon
• Origin: China
• Production Capacity: 5000kg/Month

Product Description

 

Product name	Hydroxyurea
CAS	127-07-1
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Product Name:Hydroxyurea
CAS:127-07-1
MF:CH4N2O2
MW:76.05
EINECS:204-821-7
Mol File:127-07-1.mol  
Melting point:135-140 °C
Boiling point:136.04°C (rough estimate)
Density 1.457±0.06 g/cm3(Predicted)
refractive index 1.4840 (estimate)
storage temp. 2-8°C
solubility H2O: 50 mg/mL
pka10.56±0.23(Predicted)
form powder
color white
Water Solubility soluble








Description
Hydroxyurea is a kind of anti-cancer drug for the treatment of chronic myeloid leukemia. At as early as the 1920s, it had been observed that hydroxyurea can cause the rabbits to produce megaloblastic cell similar as pernicious anemia and can inhibit leukocyte generation. In 1963 it had been found of its inhibitory effect on murine leukemia L1210. Hydroxyurea can induce bacteria to produce a toxic molecule itself to achieve the purpose of killing bacteria.
Hydroxy urea is a kind of nucleoside diphosphate reductase inhibitor and can inhibit the reduction from nucleotide to deoxynucleotide, interfering with the biosynthesis of purine and pyrimidine bases and selectively blocking the DNA synthesis. It can also cause partial inhibition of the conversion of ribonucleotides into deoxyribonucleotides. However, it has no blocking effect on RNA and protein synthesis. Hydroxyurea belongs to cycle specific drugs and is sensitive to S phase cell and can induce the hematologic remission of chronic myeloid leukemia. Compared with an alkylating agent busulfan and melphialan, it causes low incidence of secondary leukemia. The myelosuppressive effects of hydroxyurea will last for several days to several weeks which is easier to control compared with the alkylating agent. Clinically hydroxyurea is suitable or the treatment of chronic myeloid leukemia, acute lymphocytic and acute non-lymphocytic leukemia accompanied with high cell count, idiopathic thrombocythemia, polycythemia vera, prevention of retinoic acid syndrome in acute myeloid leukemia and treatment of sickle cell anemia with frequent episodes of pain. In addition, hydroxyurea have a certain effect on the treatment of head and neck cancer, recurrent metastatic ovarian cancer, renal cancer and so on.


GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company phi
osophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.